Patients with inflammatory bowel disease who receive immunosuppressive therapy have an increased risk of infection. Live vaccines are contraindicated in these patients because of the increased risk of unchecked replication of the attenuated vaccine microorganisms. Vedolizumab is a gut-selective biological agent with a low risk of infection approved for the treatment of inflammatory bowel disease. There are limited data on the risk of providing a live vaccine in patients receiving vedolizumab, and patients may receive live vaccines if the benefits outweigh the risks. We describe a patient with ulcerative colitis, treated with vedolizumab who received 2 live vaccines, typhoid and yellow fever, without postimmunization adverse events.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759320 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001507 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Regulated microbe vaccines: from concept to (pre-clinical) reduction to practice.
Expert Rev Vaccines
January 2025
Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
Introduction: Vaccines to prevent important infections involving, e.g. influenza viruses, severe acute respiratory syndrome-causing coronaviruses (e.
View Article and Find Full Text PDFThe combined immunization of cervical cancer therapeutic vaccine based on Listeria balanced lethal system has a significant therapeutic effect on tumor model mice.
Int Immunopharmacol
January 2025
West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. Electronic address:
Cervical cancer is the fourth most common cancer and the fourth leading cause of cancer death in women. Effective treatment of cervical cancer is urgently needed. Tumor therapeutic vaccine is a research hotspot in tumor immunotherapy, and the tumor therapeutic vaccine based on attenuated live bacteria carrier has clinical application prospect because of its clear action site and high safety.
View Article and Find Full Text PDFVaccine-Induced Immune Thrombotic Thrombocytopenia Caused by Zoetis PR-VAC PLUS in Pseudorabies Virus-Free Danish Purebred Pigs.
Vet Med Sci
March 2025
Department of Veterinary Medicine, National Chiayi University, Chiayi City, Taiwan.
This case report highlights a potential vaccine safety concern associated with the Pseudorabies virus (PRV) live vaccine, which warrants further investigation for comprehensive understanding. Vaccine-induced immune thrombotic thrombocytopenia (VITT), a novel syndrome of adverse events following adenovirus vector COVID-19 vaccines, was observed after vaccination with Zoetis PR-VAC PLUS. This led to a 100% morbidity and high mortality among PRV-free Danish purebred pigs from Danish Genetics Co.
View Article and Find Full Text PDFImproved Protective Efficacy in Rainbow Trout (Oncorhynchus mykiss) Against Vibrio anguillarum Through Immunization with a Combination of Formalin-Killed and Auxotrophic-Live V. anguillarum.
Mar Biotechnol (NY)
January 2025
Department of Aquatic Life Medicine, Pukyong National University, Busan, 48513, South Korea.
Vibriosis caused by Vibrio anguillarum has been an important bacterial disease in cultured rainbow trout (Oncorhynchus mykiss). In the present study, we evaluated the protective efficacy of a vaccine that consists of formalin-killed (FK) V. anguillarum and the alr genes knockout auxotrophic-live (AL) V.
View Article and Find Full Text PDFLive Typhoid and Yellow Fever Vaccines Administered to a Patient With Ulcerative Colitis on Vedolizumab.
ACG Case Rep J
October 2024
Department of Medicine, Division of Gastroenterology and Hepatology, School of Medicine & Public Health, University of Wisconsin-Madison, Madison, WI.
Patients with inflammatory bowel disease who receive immunosuppressive therapy have an increased risk of infection. Live vaccines are contraindicated in these patients because of the increased risk of unchecked replication of the attenuated vaccine microorganisms. Vedolizumab is a gut-selective biological agent with a low risk of infection approved for the treatment of inflammatory bowel disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!